Method for diagnosis and treatment of vascular disease
First Claim
2. The method of claim 1, wherein assaying the number of endothelial progenitor cells comprises isolating the buffy coat from a blood sample of the subject;
- culturing the buffy coat on a solid support coated with a first substrate;
isolating the non-adherent cells;
culturing the non-adherent cells on a solid support coated with a second substrate;
counting the number of colonies on the solid support.
2 Assignments
0 Petitions
Accused Products
Abstract
A method for diagnosing decreased vascular function is disclosed. The method includes assaying the number of endothelial progenitor cells. A method for detecting increased cardiovascular risk is also disclosed, as is a method for diagnosing atherosclerosis. In one example, the methods include assaying the number of endothelial progenitor cells. A method for treating a subject with decreased vascular function is disclosed. The method includes administering a therapeutically effective amount of endothelial progenitor cells to the subject. In one embodiment, the subject has atherosclerosis.
10 Citations
53 Claims
-
2. The method of claim 1, wherein assaying the number of endothelial progenitor cells comprises
isolating the buffy coat from a blood sample of the subject; -
culturing the buffy coat on a solid support coated with a first substrate;
isolating the non-adherent cells;
culturing the non-adherent cells on a solid support coated with a second substrate;
counting the number of colonies on the solid support. - View Dependent Claims (3, 7, 8)
-
-
9. A method of diagnosing increased vascular function in a subject, comprising
assaying the number of endothelial progenitor cells in a blood sample from the subject, wherein an increase in the number of endothelial progenitor cells in the sample as compared to a control indicates increased vascular function.
-
17. A method of treating a subject with decreased vascular function, comprising,
administering to the subject a therapeutically effective amount of endothelial progenitor cells, thereby increasing vascular function in the subject.
-
20. A method for screening for an agent that affects vascular function or is of use in treating a cardiovascular disease, comprising
administering a therapeutically effective amount of the agent to a subject, and assessing the number of endothelial progenitor cells in a sample from the subject; wherein an increased number of endothelial progenitor cells in the sample as compared to a control indicates that the agent affects vascular function or is of use in treating a cardiovascular disease. - View Dependent Claims (1, 4, 5, 6, 21, 23, 25, 26, 27, 29)
-
22. The method of claim 22, wherein the subject is a human.
-
25-1. The method of claim 20, wherein the sample is a blood sample.
-
28. The method of claim 20, wherein assaying the number of endothelial progenitor cells comprises
isolating the buffy coat from a blood sample of the subject; -
culturing the buffy coat on a solid support coated with a first substrate;
isolating the non-adherent cells;
culturing the non-adherent cells on a solid support coated with a second substrate;
enumerating the number of colonies on the solid support.
-
-
28-2. A method of diagnosing increased cardiovascular risk or decreased vascular function in a subject, comprising
assaying a number of senescent endothelial progenitor cells in a blood sample from the subject, wherein an increase in the number of senescent endothelial progenitor cells in the sample as compared to a control indicates increased cardiovascular risk or decreased vascular function.
-
30-47. -47. (canceled)
-
49. The method of claim 48, wherein the control is a standard value.
-
50. The method of claim 48, wherein the control is a number of senescent endothelial progenitor cells in a blood sample from a subject known not to be affected by a disease or disorder.
-
51. A method for screening for an agent of use in treating a cardiovascular disease, comprising
administering a therapeutically effective amount of the agent to a subject, and assessing the number of senescent endothelial progenitor cells in a sample from the subject; wherein a decreased number of senescent endothelial progenitor cells in the sample as compared to a control indicates that the agent is of use in treating the cardiovascular disease. - View Dependent Claims (52, 53)
Specification